NCT06336395View on ClinicalTrials.gov

Ma-Spore ALL 2020 Study

PHASE2RecruitingINTERVENTIONAL
Enrollment

500

Participants

Timeline

Start Date

March 4, 2020

Primary Completion Date

March 31, 2030

Study Completion Date

March 31, 2030

Conditions
B Lymphoblastic Leukemia
Interventions
DRUG

Prednisolone

Oral

DRUG

Dexamethasone

Oral

DRUG

Vincristine

Intravenous

DRUG

Methotrexate

Oral/ intrathecal/intravenous/subcutaneous

DRUG

L-Asparaginase

Intramuscular

DRUG

Pegylated asparaginase

Intravenous

DRUG

Erwinase

Optional for those allergic to E.coli/PEG L-asparaginase (intravenous)

DRUG

Dasatinib

Indicated only for ALL with BCR::ABL1 /BCR::ABL1-like/ tyrosine kinase fusion positive (oral)

DRUG

Imatinib

Indicated only for ALL with BCR::ABL1 /BCR::ABL1-like/ tyrosine kinase fusion positive (oral)

DRUG

Cyclophosphamide

Intravenous

DRUG

Cytarabine

Subcutaneous/ Intravenous

DRUG

Mercaptopurine

Oral

DRUG

Thioguanine

Oral

DRUG

Rituximab

Intravenous

DRUG

Doxorubicin

Intravenous

DRUG

Fludarabine

Intravenous

Trial Locations (3)

47500

RECRUITING

Subang Jaya Medical Centre, Kuala Lumpur

59100

RECRUITING

University Malaya Medical Centre, Kuala Lumpur

229899

RECRUITING

KK Women's and Children's Hospital, Singapore

All Listed Sponsors
lead

National University Hospital, Singapore

OTHER